Please login to the form below

Not currently logged in
Email:
Password:

CD3

This page shows the latest CD3 news and features for those working in and with pharma, biotech and healthcare.

Xencor’s Novartis-partnered bispecific on hold after patient deaths

Xencor’s Novartis-partnered bispecific on hold after patient deaths

CD3 is a popular domain target for bispecific antibodies as it activates T-cells to kill malignant cells. ... It’s not the first CD3-targeting bispecific to run into safety concerns.

Latest news

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Taking a lean and careful approach Taking a lean and careful approach

    Its fully human engineered CD3 antibody Foralumab has reached phase II with potential for a wide range of autoimmune and inflammatory diseases such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis,

  • Deal Watch June 2016 Deal Watch June 2016

    Both antibodies have a cytotoxic T-cell binding domain (CD3), which activates T-cells at the site of the tumour for killing of malignant cells, and a specific tumour antigen binding

  • Pharma deals during December 2014 Pharma deals during December 2014

    platform. The antibody targets both CD19 and CD3 and is being developed for the treatment of B-cell malignancies.

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).

  • Pharma deals during February 2014 Pharma deals during February 2014

    CD123 and CD3.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics